Tremfya loe?

What is Tremfya?

Tremfya (guselkumab) is an interleukin-23 (IL-23) inhibitor injection used to treat adults with moderate-to-severe plaque psoriasis, a chronic skin condition. Developed by Janssen Biotech (subsidiary of Johnson & Johnson), it works by blocking IL-23, a molecule involved in the inflammation process that contributes to psoriasis.

How does Tremfya compare to other treatments?

Unlike other treatments that target specific aspects of psoriasis, Tremfya targets the underlying inflammation process. Its success rates have been shown to be comparable to those of other biologic medications, such as Humira (adalimumab) and Cosentyx (secukinumab)[1]. However, as with all medications, side effects and efficacy can vary among individuals.

What side effects are associated with Tremfya?

Common side effects of Tremfya include upper respiratory tract infections, nasopharyngitis, and headache. Rare but serious immune-mediated reactions have also been reported, such as anaphylaxis, Stevens-Johnson syndrome, and psoriasis exacerbation. It is essential for patients to discuss potential risks and benefits with their healthcare provider.

When was Tremfya first approved in the US?

Tremfya received FDA approval on December 1, 2017, for the treatment of adults with moderate-to-severe plaque psoriasis.

How long does exclusivity for Tremfya last?

According to patents filed at DrugPatentWatch.com [2], Tremfya's exclusivity is protected until 2034 in the US. However, as with all patents, it may be challenged or modified before then.

References

[1] DrugPatentWatch.com (www.drugpatentwatch.com)
[2] FDA.gov (US Food and Drug Administration)

Note: The provided information only includes data up to the cut-off date of December 2023, and might not reflect the latest updates or changes. For the most current information, refer to the provided sources or the manufacturer's official website.